Loading Events

Aptose Biosciences KOL Data Call on HM43239 and Luxeptinib: Potential Treatment Candidates for AML

DATE: June 2, 2022

About The Event

The data call will feature Key Opinion Leaders (KOL’s) Brian Druker, M.D. (Oregon Health & Science University), Naval G. Daver, M.D. (MD Anderson Cancer Center) and Brian Andrew Jonas, M.D., Ph.D. (University of California, Davis) who will discuss the current treatment landscape and unmet medical need in treating patients with acute myeloid leukemia (AML).
The Aptose leadership team will provide a data update on their two potential treatment solutions for patients with AML and B cell malignancies: HM43239, an oral genotype-agnostic small molecule inhibitor of a constellation of kinases operative in myeloid malignancies, and Luxeptinib, a potent mutation-agnostic inhibitor of FLT3.
A question and answer session will follow the formal presentations.